Industrial and Organizational Mutations in the Medical and Pharmaceutical Sectors impulsed by Open Innovation during the Pandemic
DOI:
https://doi.org/10.54820/entrenova-2022-0035Keywords:
Open Innovation, Covid-19 Pandemic, Pharmaceutical Industry, Medical Devices, Cases StudiesAbstract
The Covid-19 pandemic tragically emphasized severe failures of health systems. In particular, the saturation of hospital infrastructures and the lack of medical devices is crucial for respiratory ventilators. The medical and pharmaceutical sectors had to find urgently new ways to innovate efficiently in R&D, to produce devices, therapeutic trials, and vaccines, and make them available on a large scale. Our work will analyze that these innovations related to Covid-19 have been largely based on Open Innovation. For that purpose, exploratory case studies will be shown that exemplify the value of implementing Open Innovation in the pandemic context. These case studies concern the pharmaceutical firm Pfizer, the biotechnology company BioNTech, and the respiratory ventilator open development coalition OxyGEN (from design company Protofy. xyz to the hospitals' network of Barcelona and manufacturer SEAT). Methodologically, these case studies build on a full referencing and systematic analysis of articles, scientific documents, and published reports related to the Open Innovation involvement of these organizations since the start of the pandemic. Based on the operative contributions from these revelatory case studies, we can show that Open Innovation is a highly efficient vector for extended partnerships for accelerated R&D and operational production contextually to pandemic emergencies.
References
Bagherzadeh, M., Markovic, S., Cheng, J., Vanhaverbeke, W. (2020), “How Does Outside-In Open Innovation Influence Innovation Performance? Analyzing the Mediating Roles of Knowledge Sharing and Innovation Strategy”, IEEE Transactions on Engineering Management, Vol.67 No.3, pp. 740–753.
Bianchi, M., Cavaliere, A., Chiaroni, D., Frattini, F., Chiesa, V. (2011), “Organisational modes for Open Innovation in the bio-pharmaceutical industry: An exploratory analysis”, Technovation, Vol.31 No.1, pp. 22–33.
Borja Hernandez Raja PriyadarsiniSambandan. (2015), “Open Innovation in Pharmaceutical Industry : A case study of Eli Lilly Open Innovation in Pharmaceutical Industry”, A case study of Eli Lilly, pp. 1–43.
Chesbrough, H. (2003), Open Innovation: The new imperative for creating and profiting from technology, Harvard Bu.
Chesbrough, H. (2019), Open innovation results: Going beyond the hype and getting down to business, Oxford Uni.
Chesbrough, H. (2020), “To recover faster from Covid-19, open up: Managerial implications from an open innovation perspective”, Industrial Marketing Management, Vol. 88, pp. 410-413.
Chesbrough, H., Rosenbloom, R. S. (2002), “The role of the business model in capturing value from innovation: evidence from Xerox Corporation’s technology spin-off companies”, Industrial and Corporate Change, Vol.11 No.3, pp. 529–555.
Chou, C., Yang, K.-P., Chiu, Y.-J. (2016), “Coupled open innovation and innovation performance outcomes: Roles of absorptive capacity”, Corporate Management Review, Vol.36 No.1, pp. 37–68.
Cohen, W. M., Levinthal, D. A. (1990), “Absorptive capacity: A new perspective on learning and innovation”, Administrative Science Quarterly, Vol. 35 No.1, pp. 128–152.
Dahlander, L., & Gann, D. M. (2010), “How open is innovation?”, Research Policy, Vol.39 No.6, pp. 699–709.
Enkel, E., Gassmann, O., Chesbrough, H. (2009), “Open R&D and open innovation: Exploring the phenomenon”, R&D Management, Vol.39 No.4, pp. 311–316.
Fetterhoff, T. J., Voelkel, D. (2006), “Managing Open Innovation in Biotechnology”, Research-Technology Management, Vol.49 No.3, pp. 14–18.
Gausemeier, J., Echterhoff, N., Kokoschka, M., Wall, M. (2011), Thinking ahead the Future of Additive Manufacturing - Analysis of Promising Industries. Heinz Nixdorf Institute, Paderborn.
Henkel, J. (2006), “Selective revealing in open innovation processes: The case of embedded Linux”, Research Policy, Vol.35 No.7, pp. 953–969.
Hunter, J., Stephens, S. (2010), “Is open innovation the way forward for big pharma?”, Nature Reviews Drug Discovery, Vol.9 No.2, pp. 87–88.
Laursen, K., Salter, A. J. (2014), “The paradox of openness: Appropriability, external search and collaboration”, Research Policy, Vol.43 No.5, pp. 867–878.
Lu, Q., Chesbrough, H. (2021), Measuring open innovation practices through topic modelling: Revisiting their impact on firm financial performance, Technovation, Vol.114, pp. 102434.
Madhok, A., Osegowitsch, T. (2000), “The International Biotechnology Industry: A Dynamic Capabilities Perspective”, Journal of International Business Studies, Vol.31 No.2, pp. 325–335.
Mazzola, E., Bruccoleri, M., Perrone, G. (2012), “The effect of inbound, outbound and coupled innovation on performance”, International Journal of Innovation Management, Vol.16 No.6.
Mazzola, E., Bruccoleri, M., Perrone, G. (2016), “Open innovation and firms’ performance: State of the art and empirical evidences from the bio-pharmaceutical industry”, International Journal of Technology Management, Vol.70 No.2–3, pp. 109–134.
Ostrom, E., Hess, C. (2007), understanding knowledge as a commons: from theory to practice. Cambridge, Massachusetts: MIT Press. 382 pages.
Patrucco, A. S., Trabucchi, D., Frattini, F., Lynch, J. (2022), ”The impact of Covid‐19 on innovation policies promoting Open Innovation”, R&D Management, Vol.52 No.2, pp. 273-293.
Pfizer (2022) “Partners: Teaming up for Breakthroughs” avaible at: https://www.pfizer.com/about/partners/research-and-business-development-partnerships
Pfizer (23.4 2020), “Covid-19 - recherche en vaccins et traitements, donations et subventions : pfizer engagé sur plusieurs fronts dans la lutte contre l’épidémie”, available at: https://www.pfizer.fr/covid-19-pfizer-annonce-les-premiers-essais-cliniques-de-ses-candidats-vaccins-en-partenariat-avec
Pfizer (11.11. 2020), “Pfizer et biontech signent un accord pour fournir à l'union européenne 200 millions de doses de leur candidat-vaccin à base d’arn messager bnt162b2 contre contre le sars-cov-2”available at https://www.pfizer.fr/pfizer-et-biontech-signent-un-accord-pour-fournir-lunion-europeenne-200-millions-de-doses-de-leur
Pfizer (08.10. 2020), “Les leaders de l'industrie pharmaceutique s'unissent pour faire progresser la science”, available at: https://www.pfizer.fr/les-leaders-de-lindustrie-pharmaceutique-sunissent-pour-faire-progresser-la-science
Rayna, T., Striukova, L., Darlington, J. (2015), “Co-creation and user innovation: The role of online 3D printing platforms”, Journal of Engineering and Technology Management, Vol.37, pp. 90-102.
Rayna, T., Striukova, L. (2016),” From rapid prototyping to home fabrication: How 3D printing is changing business model innovation”, Technological Forecasting and Social Change, Vol.102, pp. 214-224.
Schuhmacher, A., Germann, P. G., Trill, H., Gassmann, O. (2013), “Models for open innovation in the pharmaceutical industry”, Drug Discovery Today, Vol.18 No.23–24, pp. 1133–1137.
West, J., Kuk, G. (2016), “The complementarity of openness: How MakerBot leveraged Thingiverse in 3D printing”, Technological Forecasting and Social Change, Vol.102, pp. 169-181.
Yin, R.K. (2014), Case Study Research Design and Methods (5th ed.). Thousand Oaks. CA: Sage. 282 pages.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 ENTRENOVA - ENTerprise REsearch InNOVAtion
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
